Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LCZ 696

Known as: LCZ-696, LCZ696 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Abstract Aims To assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
AIMS The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Although most patients in the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global… Expand
  • figure 1
  • table 1
  • table 3
  • table 4
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with… Expand
  • figure 1
  • table 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Review
2014
Review
2014
Neprilysin is an enzyme that contributes to the breakdown of the biologically active natriuretic peptides and several other… Expand
  • table 1
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Aim To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison… Expand
  • table 2
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Heart failure with preserved ejection fraction is associated with substantial morbidity and mortality, but effective… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND LCZ696 is a first-in-class inhibitor of the angiotensin II receptor and neprilysin. We aimed to establish whether the… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?